Allergan PLC spent much of its third quarter earnings call on Nov. 1 talking less about its financial results and more about expectations for 2018 when, following a crucial patent litigation loss, Restasis (cyclosporine) generics may enter the market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?